Merifatin tablets 500mg, No. 60

• Diabetes mellitus type 2 (non-insulin dependent) with ineffective diet therapy and exercise, in obese patients: in adults - as monotherapy or in combination with other oral hypoglycemic agents or with insulin;

• in children aged 10 years and older - as monotherapy or in combination with insulin.

It is taken orally, during or after a meal. The dose and frequency of administration depends on the dosage form used. In monotherapy, the initial single dose for adults is 500 mg, depending on the dosage form used, the frequency of administration is 1-3 times / day. It is possible to use 850 mg 1-2 times / day. If necessary, the dose is gradually increased at intervals of 1 week. up to 2-3 g / day When monotherapy for children aged 10 years and older, the initial dose is 500 mg or 850 1 time / day or 500 mg 2 times / day. If necessary, with an interval of at least 1 week, the dose can be increased to a maximum of 2 g / day in 2-3 doses. After 10-15 days, the dose must be adjusted based on the results of the determination of glucose in the blood. When combined therapy with insulin, the initial dose metformin is 500-850 mg 2-3 times / day.The insulin dose is selected based on the results of the determination of glucose in the blood.

White film-coated tablets, oblong, biconvex; in cross section, the core is white or almost white.

1 tab.

metformin hydrochloride 500 mg

Excipients: hypromellose 2208 - 5 mg, povidone K90 (Kollidon 90F) - 20 mg, sodium stearyl fumarate - 5 mg.

• Acute or chronic metabolic acidosis, diabetic ketoacidosis, diabetic precoma, and coma;

• renal failure, impaired renal function (CC <60 ml / min);

• dehydration, severe infection, hypoglycemic shock, which can lead to impaired renal function;

• clinically pronounced symptoms of acute and chronic diseases that can lead to the development of tissue hypoxia (including heart failure, acute myocardial infarction, respiratory failure);

• the use of contrasting iodine-containing substances for intravascular administration (including when performing intravenous urography, intravenous cholangiography, angiography, CT);

• acute alcohol intoxication, chronic alcoholism;

• hypersensitivity to metformin.

pharmachologic effect

Oral hypoglycemic agent from the biguanide group (dimethylbiguanide). The mechanism of action of metformin is associated with its ability to suppress gluconeogenesis, as well as the formation of free fatty acids and fat oxidation. Increases the sensitivity of peripheral receptors to insulin and glucose utilization by cells. Metformin does not affect the amount of insulin in the blood, but changes its pharmacodynamics by reducing the ratio of bound to free insulin and increasing the ratio of insulin to proinsulin. Metformin stimulates glycogen synthesis by acting on glycogen synthetase. Increases the transport capacity of all types of membrane glucose transporters. Delays the absorption of glucose in the intestine. Reduces the level of triglycerides, LDL, VLDL.Metformin improves the fibrinolytic properties of blood by inhibiting tissue-type plasminogen activator inhibitor. While taking metformin, the patient's body weight either remains stable or decreases moderately.

Pharmacokinetics

After oral administration, metformin is slowly and incompletely absorbed from the gastrointestinal tract. Cmax in plasma is reached after about 2.5 hours. With a single dose of 500 mg, the absolute bioavailability is 50-60%. With the simultaneous intake of food, the absorption of metformin is reduced and delayed. Metformin is rapidly distributed into body tissues. Practically does not bind to plasma proteins. It accumulates in the salivary glands, liver and kidneys. It is excreted by the kidneys unchanged. T1 / 2 from plasma is 2-6 hours. In case of impaired renal function, accumulation of metformin is possible.

Side effect

From the digestive system: possible (usually at the beginning of treatment) nausea, vomiting, diarrhea, flatulence, abdominal discomfort; in isolated cases - impaired liver function indicators, hepatitis (disappear after stopping treatment). From the side of metabolism: very rarely - lactic acidosis (discontinuation of treatment is required). From the side of the hematopoietic system: very rarely - impaired absorption of vitamin B12. The profile of adverse reactions in children aged 10 years and older is the same as in adults.

Application during pregnancy and lactation

Adequate and strictly controlled studies of the safety of the use of metformin during pregnancy have not been conducted. Use during pregnancy is possible in cases of extreme necessity, when the expected benefit of therapy to the mother outweighs the possible risk to the fetus. Metformin crosses the placental barrier. Metformin in small amounts is excreted in breast milk, while the concentration of metformin in breast milk can be 1/3 of the concentration in the mother's plasma. Side effects in newborns with breastfeeding while taking metformin were not observed. However, due to the limited amount of data, use during breastfeeding is not recommended. The decision to stop breastfeeding should be made in light of the benefits of breastfeeding and the potential risk of side effects in the baby.Preclinical studies have shown that metformin does not have a teratogenic effect in doses that are 2-3 times higher than the therapeutic doses used in humans. Metformin has no mutagenic potential and does not affect fertility.

Application for violations of liver function

Contraindicated in severe liver dysfunction.

Application for impaired renal function

Contraindicated in severe renal impairment.

Use in elderly patients

It is not recommended to use metformin in patients over 60 years old, which is associated with an increased risk of lactic acidosis.

special instructions

Not recommended for use in acute infections, exacerbation of chronic infectious and inflammatory diseases, trauma, acute surgical diseases, the risk of dehydration. Do not use before surgery and within 2 days after surgery. Care should be taken to use metformin in elderly patients and those performing heavy physical work, which is associated with an increased risk of lactic acidosis. In elderly patients, asymptomatic renal dysfunction is often observed. Particular care is required if renal impairment is triggered by the intake of antihypertensive drugs or diuretics, as well as NSAIDs. If during treatment the patient has muscle cramps, indigestion (abdominal pain) and severe asthenia, then it should be borne in mind thatthat these symptoms may indicate the onset of the development of lactic acidosis. During the period of treatment, it is necessary to monitor kidney function; determination of the lactate content in plasma should be carried out at least 2 times a year, as well as when myalgia appears. When metformin is used as monotherapy in accordance with the dosing regimen, hypoglycemia usually does not occur. However, when combined with insulin or sulfonylurea derivatives, there is a risk of hypoglycemia. In such cases, it is necessary to especially carefully monitor the concentration of glucose in the blood. During the period of treatment, patients should avoid drinking alcohol because of the risk of developing lactic acidosis. Preclinical studies have shown that metformin has no carcinogenic potential.determination of the lactate content in plasma should be carried out at least 2 times a year, as well as when myalgia appears. When metformin is used as monotherapy in accordance with the dosing regimen, hypoglycemia usually does not occur. However, when combined with insulin or sulfonylurea derivatives, there is a risk of hypoglycemia. In such cases, it is necessary to especially carefully monitor the concentration of glucose in the blood. During the period of treatment, patients should avoid drinking alcohol because of the risk of developing lactic acidosis. Preclinical studies have shown that metformin has no carcinogenic potential.determination of the lactate content in plasma should be carried out at least 2 times a year, as well as when myalgia appears. When metformin is used as monotherapy in accordance with the dosing regimen, hypoglycemia usually does not occur. However, when combined with insulin or sulfonylurea derivatives, there is a risk of hypoglycemia. In such cases, it is necessary to especially carefully monitor the concentration of glucose in the blood. During the period of treatment, patients should avoid drinking alcohol because of the risk of developing lactic acidosis. Preclinical studies have shown that metformin has no carcinogenic potential.However, when combined with insulin or sulfonylurea derivatives, there is a risk of hypoglycemia. In such cases, it is necessary to especially carefully monitor the concentration of glucose in the blood. During the period of treatment, patients should avoid drinking alcohol because of the risk of developing lactic acidosis. Preclinical studies have shown that metformin has no carcinogenic potential.However, when combined with insulin or sulfonylurea derivatives, there is a risk of hypoglycemia. In such cases, it is necessary to especially carefully monitor the concentration of glucose in the blood. During the period of treatment, patients should avoid drinking alcohol because of the risk of developing lactic acidosis. Preclinical studies have shown that metformin has no carcinogenic potential.

Drug interactions

With simultaneous use with sulfonylurea derivatives, acarbose, insulin, salicylates, MAO inhibitors, oxytetracycline, ACE inhibitors, with clofibrate, cyclophosphamide, the hypoglycemic effect of metformin may increase. With simultaneous use with GCS, hormonal contraceptives for oral administration, danazol, epinephrine, glucagon, thyroid hormones, phenothiazine derivatives, thiazide diuretics, nicotinic acid derivatives, it is possible to reduce the hypoglycemic effect of metformin. In patients receiving metformin, the use of iodine-containing contrast agents for the purpose of diagnostic studies (including intravenous urography, intravenous cholangiography, angiography, CT) increases the risk of developing acute renal dysfunction and lactic acidosis. These combinations are contraindicated.Beta2-adrenergic agonists in the form of injections increase the concentration of glucose in the blood due to the stimulation of ?2-adrenergic receptors. In this case, it is necessary to control the concentration of glucose in the blood. It is recommended to prescribe insulin if necessary. Concomitant use of cimetidine may increase the risk of developing lactic acidosis. Concomitant use of loop diuretics can lead to the development of lactic acidosis due to possible functional renal failure. Concomitant use with ethanol increases the risk of developing lactic acidosis. Nifedipine increases the absorption and Cmax of metformin. Cationic drugs (amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and vancomycin) secreted in the renal tubules,compete with metformin for tubular transport systems and can lead to an increase in its Cmax.